BJDX stock sentiment todayBluejay Diagnostics Inc
Sentiment verdict
Gossip first, financials second — COLD at 85% confidence.
Last updated · cached analysis, refreshes periodically
BJDX
Bluejay Diagnostics IncBJDX is a high-risk micro-cap diagnostic play struggling with NASDAQ compliance and heavy dilution via reverse splits despite its clinical progress in sepsis testing.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for BJDX. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the 1-for-4 reverse stock split aimed at maintaining NASDAQ listing requirements, which typically signals distress. However, speculative interest is driven by a critical Oct 23 deadline for their Symphony System sepsis test cartridge site setup.
- ·1-for-4 Reverse Stock Split
- ·Sepsis test clinical trial data releases
- ·NASDAQ delisting fears
- ·Speculative pre-market volatility
Financial
Bluejay is a pre-revenue medical device company with a high burn rate and limited cash runway, evidenced by frequent equity raises and structural share consolidations.
- ·Negative Operating Income
- ·Frequent shareholder dilution
- ·Low market capitalization (Micro-cap)
- ·High cash burn-to-revenue ratio
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders bought a net $48K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Regulatory rejection of the Symphony IL-6 test by the FDA
- ·Further dilution or delisting if the stock price fails to hold above $1.00 post-split
- ·Extreme price volatility common in low-float clinical-stage biotechs
Peer temperature
How direct competitors stack up against BJDX right now.
- NEUTRALTTOOT2 Biosystems
WARMER — Also in the sepsis space and highly volatile, but has a larger established product portfolio and higher brand recognition among hospital labs.
See full analysis → - HOTQDELQuidelOrtho
HOTTER — A profitable industry leader with diversified revenue streams and massive scale that BJDX cannot currently match.
See full analysis → - NEUTRALENZEnzo Biochem
WARMER — Better capitalized with a more stable balance sheet, though currently undergoing significant corporate restructuring.
See full analysis →
- BJDX-34.9%
- TTOO+16.7%
- QDEL+25.7%
- ENZ—
Recent headlines
- TradingViewBluejay Diagnostics, Inc. (BJDX) Sets 1-for-4 Reverse Stock Split
- MoomooBluejay Diagnostics Announces 1-for-4 Reverse Stock Split
- Stock TitanA cartridge site for a sepsis test is set up ahead of Bluejay's Oct. 23 deadline.
- ACCESS NewswireBluejay Diagnostics Announces 1-for-4 Reverse Stock Split
- ChartMillThese stocks are moving in today's pre-market session
- BenzingaWhy Is Bluejay Diagnostics Stock Soaring Tuesday? - Bluejay Diagnostics (NASDAQ:BJDX)
AI-generated analysis for informational purposes only. Not financial advice.